Cellectar Biosciences Restates Financials

TL;DR

Cellectar's financials are toast, don't trust old numbers.

AI Summary

Cellectar Biosciences, Inc. announced on August 9, 2024, that it will not rely on previously issued financial statements for the fiscal year ended December 31, 2023, and interim periods thereafter. This decision stems from an ongoing internal review concerning the classification of certain convertible notes and their associated warrants.

Why It Matters

Investors should be aware that previously reported financial figures may be inaccurate, potentially impacting the company's perceived financial health and valuation.

Risk Assessment

Risk Level: medium — The need to restate financials indicates potential accounting issues that could lead to further complications or investor uncertainty.

Key Players & Entities

• Cellectar Biosciences, Inc. (company) — Registrant
• August 9, 2024 (date) — Date of Report
• December 31, 2023 (date) — Fiscal Year End

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB NASDAQ Check the a

Filing Documents

• tm2421322d1_8k.htm (8-K) — 28KB
• 0001104659-24-087859.txt ( ) — 197KB
• clrb-20240809.xsd (EX-101.SCH) — 3KB
• clrb-20240809_lab.xml (EX-101.LAB) — 33KB
• clrb-20240809_pre.xml (EX-101.PRE) — 22KB
• tm2421322d1_8k_htm.xml (XML) — 3KB

02. Non-Reliance on Previously Issued Financial

Item 4.02. Non-Reliance on Previously Issued Financial On August 9, 2024, Cellectar Biosciences, Inc. Board of Directors (the "Board") concluded that the Company's previously-issued (i) audited consolidated financial interim condensed consolidated financial statements for the periods ending March 31, 2023, June 30, 2023, September 30, 2023, and March 31, 2024 contained in its Quarterly Reports on Form 10-Q (collectively, the "Non-Reliance Periods"), as well as its disclosures related to such financial statements, including any reports, earnings releases, and investor presentations, and related communications issued by or on behalf of the Company with respect to the Non-Reliance Periods, should no longer be relied upon due to errors in such financial statements, and therefore a restatement of these prior financial statements is required. The determination by the Board was made upon the recommendation of the Audit Committee (the "Audit Committee") of the Board and after consultation with the Company's management team. The Company discussed these matters with Deloitte & Touche LLP ("Deloitte"), the Company's current independent registered accounting firm and informed Baker Tilly US, LLP ("Baker Tilly"), the Company's former independent registered accounting firm during the relevant periods. Subsequent to its engagement of Deloitte in July 2024 as its independent registered public accounting firm, the Company determined that it was necessary to re-evaluate the Company's accounting treatment for the warrants that it issued as part of the financing completed in October 2022. As a result of this analysis, the Company expects that it will restate the financial statements for the Non-Reliance Periods (the "Restatement"); additionally, the Company will also assess any

Forward-Looking Statements

Forward-Looking Statements This Item 4.02 of this Current Report on Form 8-K contains "forward-looking" statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking of accounting matters and audit of the Company's financial statements; the Company's plans to file the Pending 10-Qs and a super 10-K with the restated results; expectations with respect to how the adjustments will impact the Company's financial to prior or current lenders; and the Company's plans, objectives and intentions, that are not historical facts generally. These implied by the forward-looking statement, including without limitation: the final outcome of the evaluation of accounting matters and the impact of the adjustments to the Company's financial statements; the discovery of additional and unanticipated information during the re-evaluation and audit of the Company's financial statements, including it evaluation of effectiveness of internal control over financial reporting; changes in assumptions regarding how the evaluation will impact the Company's financial results; the application of accounting or tax principles in an unanticipated manner; the possibility that the Nasdaq may delist the Company's common stock; risks related to the Company's ability to implement and maintain effective internal control over financial reporting in the future; and the impact of these factors on the Company's performance and outlook. See also other risks that are described in "Risk Factors"

View Full Filing

View this 8-K filing on SEC EDGAR